<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447483</url>
  </required_header>
  <id_info>
    <org_study_id>17GENE22</org_study_id>
    <nct_id>NCT03447483</nct_id>
  </id_info>
  <brief_title>Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).</brief_title>
  <acronym>MOTIVATE</acronym>
  <official_title>Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicentric, prospective cohort study of 150 patients aiming to model&#xD;
      evolution of toxicity over time in patients with solid tumor and starting first cycle of&#xD;
      Immune Checkpoint Inhibitor (ICI) treatment.&#xD;
&#xD;
      The study will be conducted on a population of patients treated with ICI in the context of&#xD;
      routine care. The follow-up during the treatment period and the clinical, biological and&#xD;
      radiological assessments will be performed according to the standard of each centre.&#xD;
&#xD;
      The study data (immune-related adverse events) will be collected during each administration&#xD;
      of the treatment.&#xD;
&#xD;
      A questionnaire will be completed by the patient before the treatment administrations.&#xD;
&#xD;
      Patients will be followed until disease progression or up to 12 months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of toxicities evaluated according to the classification of the Common for Toxicity Criteria for Adverse Events (CTCAE) V4.03</measure>
    <time_frame>12 months by patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to appearance of toxicity</measure>
    <time_frame>12 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients for which treatment was restarted among those who had stopped treatment for the management of an immune-related Adverse Event (irAE)</measure>
    <time_frame>12 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the QLQ-C30 questionnaire</measure>
    <time_frame>12 months by patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Cohort of patients starting a treatment by ICI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients starting a treatment by ICI</intervention_name>
    <description>Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:&#xD;
every 6 weeks for treatment regimen administered every 2 or 3 weeks&#xD;
at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks</description>
    <arm_group_label>Cohort of patients starting a treatment by ICI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; or = 18 years old&#xD;
&#xD;
          2. Patient with a solid tumor whatever the organ&#xD;
&#xD;
          3. Patient receiving an Immune Checkpoint Inhibitor treatment&#xD;
&#xD;
          4. Patient starting first cycle of Immune Checkpoint Inhibitor treatment whatever the&#xD;
             treatment line&#xD;
&#xD;
          5. Patient affiliated to the french social security system&#xD;
&#xD;
          6. Patient must provide written informed consent prior to inclusion in the study and any&#xD;
             study-specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who must receive a treatment other than Immune Checkpoint Inhibitor&#xD;
&#xD;
          2. Patient with contraindication to the use of a checkpoint inhibitor (e.g., auto immune&#xD;
             disorders requiring an immunosuppressive therapy)&#xD;
&#xD;
          3. Pregnant or breastfeeding women&#xD;
&#xD;
          4. Any psychological, familial, geographical or sociological condition potentially&#xD;
             preventing the medical follow-up and/or study procedures&#xD;
&#xD;
          5. Patient protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH ALBI</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Castres</name>
      <address>
        <city>Castres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer de Montpellier (Icm)</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>immune-related Adverse Event</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

